Key facts
- This page summarizes Jonathan Allan's Form 4 filing for Stoke Therapeutics, Inc. (STOK).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 22 May 2024, 16:15.
Jonathan Allan - 20 May 2024 Form 4 Insider Report for Stoke Therapeutics, Inc. (STOK)
- Reporting relationship
- GENERAL COUNSEL & CORP SEC
- Issuer ticker
- STOK
- Reported as of
- 20 May 2024
- Net transaction value
- -$68,532
- SEC form
- 4
- Accepted by SEC
- 22 May 2024, 16:15:34 UTC
- Prior SEC filing
- 01 Apr 2024
- Next SEC filing
- 03 Dec 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jonathan Allan
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jonathan Allan filed Form 4 for Stoke Therapeutics, Inc. (STOK) on 22 May 2024.
Change
- Previous filing in this sequence was filed on 01 Apr 2024.
- Current net transaction value: -$68,532.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
STOK
transaction
Common Stock
Options Exercise
- Transaction value
- $60,795
- Shares
- +8,599
- Change %
- +331%
- Price
- $7.07
- Shares after
- 11,197
- Date
- 20 May 2024
- Ownership
- Direct
STOK
transaction
Common Stock
Sale
- Transaction value
- $129,327
- Shares
- -8,599
- Change %
- -77%
- Price
- $15.04
- Shares after
- 2,598
- Date
- 20 May 2024
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
STOK
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -8,599
- Change %
- -25%
- Price
- $0.000000
- Shares after
- 25,801
- Date
- 20 May 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 8,599
- Exercise price
- $7.07
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 3 footnotes
Footnote F1
The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 15, 2023 by the reporting person.
Footnote F2
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.16 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote
Footnote F3
The option vested or vests as to 1/48th of the total award on January 7, 2023, with 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.